The Molecular Pharmacology Shared Resource (MPSR) provides a wide variety of services regarding clinical and preclinical anticancer pharmacology as summarized below.

For assistance, request Molecular Pharmacology Service here (PPMS Access Required):

Support Request

Signup for a new PPMS account  |  Quick guide for signing up


The MPSR works to develop and implement clinical PK/PD studies. The MPSR will coordinate and manage all specimen collection and processing for the trial principal investigator and develop new assays and conduct specimen analysis on demand to understand the PK/PD properties and potential of drug-drug interactions of tested agents.

Protocol and study development

  • Specimen collection protocols and language
  • Development of hypotheses and objectives for translational studies
  • HIPAA compliance
  • Budget development

Specimen acquisition and management

  • Collection and processing of specimens
  • Specimen log-in, de-identification and storage
  • Provide periodic updates on specimen accrual to study PI

Specimen analysis

  • Develop new assays for targeted analysis of drugs, metabolites, and specific biomarkers
  • Coordinate or perform specimen analysis
    • Drugs and metabolites
    • Amino acids profiles
    • Biomarkers
    • DNA mutations
    • RNA expression
    • Genetic Polymorphism
    • Plasma protein/nucleotide profiling
    • Immunohistochemistry, multispectral imaging
  • Data synthesis and analysis


The MPSR can design and conduct comprehensive experiments for in vitro and in vivo testing of novel agents or therapeutic combinations for discovery and proof-of-principle. Such studies can provide rationale for clinical trial development. A wide variety of molecular pharmacological approaches, and clinically-relevant cell and xenograft animal models can be utilized.

  • New assays and methodologies development
  • Preclinical modeling
    • Novel agent activity
    • DM/PK/PD and integrated PK-PD modeling
    • Drug-drug interactions
    • Combination effects: synergism, addition, or antagonism
    • Cancer metabolism, glycolysis, and mitochondrial functions
    • Target validation
    • Pharmacological mechanisms
  • One-of-a-kind bioengineered RNAi agents to study cancer biology and assess new therapeutic strategies